Literature DB >> 16202777

Delayed diagnosis of cystic fibrosis and the family perspective.

Martin Kharrazi1, Lisa D Kharrazi.   

Abstract

The impact of delayed diagnosis of cystic fibrosis (CF) on families is poorly described, especially in the United States. Studies outside the United States indicate that misdiagnosis leads to increased anxiety, guilt, anger, and mistrust of the medical profession, and late diagnosis leads to more negative feelings about the pre-diagnostic period and less confidence in the medical profession. To describe the impact of delayed diagnosis on US families, diagnostic stories were requested on the CF Research, Inc, e-mail list in September 2003. Twenty diagnostic stories were returned, and 20 additional stories were found on the Cystic-L listserv dating back to 1997. Stories were condensed into that of a single family and a qualitative description of the symptoms, medical and family responses at different life stages provided, along with health and family sequelae if the diagnosis had occurred at various ages. Responses to symptoms differed by age. Families were frustrated and stressed by diagnostic incompetence. Ineffectual care led to long-term anxiety, emotional trauma, and self-doubt. Families suffered economic losses. Relationships with one another and with doctors were seriously affected. CF parents consistently expressed that newborn screening would help others avoid the pain they suffered by not knowing the diagnosis earlier.

Entities:  

Mesh:

Year:  2005        PMID: 16202777     DOI: 10.1016/j.jpeds.2005.08.011

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  9 in total

1.  Long-term follow-up of cystic fibrosis newborn screening: psychosocial functioning of adolescents and young adults.

Authors:  Audrey Tluczek; Anita Laxova; Adam Grieve; Anne Heun; Roger L Brown; Michael J Rock; William M Gershan; Philip M Farrell
Journal:  J Cyst Fibros       Date:  2013-10-21       Impact factor: 5.482

2.  Comparison of quantitative sweat chloride methods after positive newborn screen for cystic fibrosis.

Authors:  Theresa A Laguna; Nan Lin; Qi Wang; Bonnie Holme; John McNamara; Warren E Regelmann
Journal:  Pediatr Pulmonol       Date:  2012-01-03

3.  Why Do Parents Want to Know their Child's Carrier Status? A Qualitative Study.

Authors:  Danya F Vears; Clare Delany; John Massie; Lynn Gillam
Journal:  J Genet Couns       Date:  2016-05-19       Impact factor: 2.537

Review 4.  Atypical cystic fibrosis: identification in the primary care setting.

Authors:  Carrie A Schram
Journal:  Can Fam Physician       Date:  2012-12       Impact factor: 3.275

5.  Living with primary ciliary dyskinesia: a prospective qualitative study of knowledge sharing, symptom concealment, embarrassment, mistrust, and stigma.

Authors:  Simon Whalley; I C McManus
Journal:  BMC Pulm Med       Date:  2006-10-13       Impact factor: 3.317

6.  A Study to Explore the Parental Impact and Challenges of Self-Management in Children and Adolescents Suffering with Lymphedema.

Authors:  Christine Moffatt; Aimee Aubeeluck; Elodie Stasi; Roberto Bartoletti; Christine Aussenac; Dario Roccatello; Isabelle Quere
Journal:  Lymphat Res Biol       Date:  2019-04       Impact factor: 2.589

7.  Why does it take so long for rare disease patients to get an accurate diagnosis?-A qualitative investigation of patient experiences of hereditary angioedema.

Authors:  Moeko Isono; Minori Kokado; Kazuto Kato
Journal:  PLoS One       Date:  2022-03-18       Impact factor: 3.240

8.  Cystic fibrosis newborn screening programs: implications of the CFTR variant spectrum in nonwhite patients.

Authors:  Lynn Pique; Steve Graham; Michelle Pearl; Martin Kharrazi; Iris Schrijver
Journal:  Genet Med       Date:  2016-05-05       Impact factor: 8.822

9.  Information needs of physicians regarding the diagnosis of rare diseases: a questionnaire-based study in Belgium.

Authors:  Liese Vandeborne; Eline van Overbeeke; Marc Dooms; Birgit De Beleyr; Isabelle Huys
Journal:  Orphanet J Rare Dis       Date:  2019-05-04       Impact factor: 4.123

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.